Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer

cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

Contact: Ina Cu

              Investor Relations

              650-266-3200


CONTACT: Ina Cu, Investor Relations of Cell Genesys, Inc.,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 /PRNewswire-iReach/ ... Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a ... and Chinese Oxybutynin Hydrochloride industry. The report ... Hydrochloride including its classification, application and manufacturing ... China,s top manufacturers of Oxybutynin Hydrochloride listing ...
(Date:9/19/2014)... 2014  The board of directors of AbbVie Inc. ... dividend of $0.42 per share.  The ... of record at the close of business on Oct. ... global, research-based biopharmaceutical company formed in 2013 following separation ... expertise, dedicated people and unique approach to innovation to ...
(Date:9/19/2014)... , Sept. 19, 2014 Merck (NYSE: MRK ... and Canada , is teaming with celebrity ... Diabetes: Logra Tus Metas , an educational program encouraging Hispanics with ... -- a key treatment goal to help reduce the risk of ... are at a higher risk for developing type 2 diabetes ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
(Date:9/20/2014)... (PRWEB) September 20, 2014 New ... and Market Analysis to 2023?. The asthma market ... as it has become saturated with relatively efficacious ... corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), ... increasing generic competition. However, the launch of seven ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Traditionally dentists have ... of South Charlotte Dentistry is re-visiting that advice ... the effects that coffee and wine have on oral health. ... studies determined that coffee may be beneficial in protecting against ... , The study on coffee was from the ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 QueenBeeTickets.com is ... young star’s tour performances. She will visit many cities ... February until the 16th of April. , Click ... Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s fans ... to see their favorite young singer in a live ...
(Date:9/20/2014)... 2014 “Motherhood is a wonderful gift and ... their latest article , “We know that you want ... that’s what we want to do as well.” , The ... should expect from their Family Physicians who practice obstetrics while ... motherhood. , To learn more about Community Health Center ...
(Date:9/19/2014)... September 19, 2014 “Copay coupons,” a ... of brand drugs among patients with prescription drug coverage, ... to a new report from the Department of ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... the federal government. , The report highlights that two ...
Breaking Medicine News(10 mins):Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2
... new studies out this week add to the body of research ... of adverse mental health effects. The two peer-reviewed papers were published ... Journal of Psychiatric Research . Both had strong methodology and controls ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , ...
... the connection , , FRIDAY, Dec. 5 (HealthDay News) -- ... health and your respiratory health -- specifically asthma. , ... more likely to have asthma than those who described ... , If you,re a person with both asthma and ...
... Disabled Teenager and His Family , , ... in his 13 years, Dustin Monk will have reason to smile ... Store ( www.thescooterstore.com ), Dustin will finally have the mobility and ... Today, just weeks after Dustin,s father, Danny Monk, contacted ...
... kids under 2 poses toxicity issues because of use ... to the decongestant pseudoephedrine, found in many cough, cold ... in the United States. , This is especially true ... risk for toxicity and for whom safe dosing recommendations ...
... Training Drills Prepare Health Care Workers for Future Emergencies ... Dec. 5 AmeriCares, a nonprofit international relief organization, ... public-private partners to expand disaster preparedness and trauma training ... helping health care systems prepare for large-scale disasters, whether ...
... BOULDER, Colo., Dec. 5 Encision Inc.,(OTC Bulletin Board: ECIA) ... on the OTC Bulletin Board ("OTCBB") with a trading symbol ... will continue to be a Securities and Exchange Commission,("SEC") reporting ... its,required SEC and regulatory filings. There is no listing fee ...
Cached Medicine News:Health News:Poor Mental Health May Boost Asthma Risk 2Health News:The SCOOTER Store Donates Power Wheelchair to Texas Teenager With Rare Genetic Disorders 2Health News:The SCOOTER Store Donates Power Wheelchair to Texas Teenager With Rare Genetic Disorders 3Health News:Decongestant Exposure Needs Closer Look 2Health News:AmeriCares Investing in Disaster Preparedness in India 2Health News:AmeriCares Investing in Disaster Preparedness in India 3Health News:Encision Announces Quoting of Common Stock on the OTC Bulletin Board 2
... of doublet objective and high power negative ... 3.0x. The true benefit of this system ... focal clarity is made possible due to ... lightweight aluminum bar and individual interpupillary adjustment ...
Used for maintaining and forming the anterior chamber by the injection and removal of fluids, air miotics, and viscoeastic substances, as well as keeping the cornea moist during surgery. 4 mm from be...
23 gauge cannula (E4969 L) with 0.33 mm aspiration port, curved shaft and polished finish. Includes Teflon irrigating sleeve (E4969 SL). Uses 60 cm (23.6 inches) of silicone tubing (N5941 5). Overall...
... with five legs for extra stability. ... 25" (total vertical travel 6"). 2" ... Comfortable, durable and fire retardant upholstery, ... other colors available by special order. ...
Medicine Products: